Jump to content

Oxigene plans phase II lung cancer trial

Recommended Posts

http://www.pharmaceutical-business-revi ... 9BE69400ED

Oxigene plans phase II lung cancer trial

6th February 2006

By Staff Writer

Oxigene is planning a phase II clinical trial in the US evaluating its lead clinical candidate, Combretastatin A4P, in the treatment of stage IIIa/IIIb non small cell lung cancer.

AdvertisementThe company will evaluate Combretastatin A4P (CA4P), in combination with concurrent chemo-radiotherapy, a widely accepted standard in the US for the treatment of unresectable stage IIIa/IIIb non small cell lung cancer (NSCLC).

The phase II clinical trial will initially enroll approximately 12 patients to assess the tolerability of the protocol and to establish the recommended dose of intravenously administered CA4P.

In other ongoing clinical trials, CA4P has been paired with chemotherapy or radiation therapy with no observed side effects beyond those typically experienced with either treatment.

The trial will then proceed to compare approximately 66 patients who will be split into an investigational group and an active control group.

"We believe this phase II clinical trial to be a key stepping stone in the path towards potential commercialization of CA4P for the treatment of NSCLC," commented Frederick Driscoll, president and CEO of Oxigene.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.